申请人:Heron Therapeutics, Inc.
公开号:US10624850B2
公开(公告)日:2020-04-21
Disclosed herein are novel pharmaceutical formulations of a neurokinin-1 (NK-1) receptor antagonist suitable for parenteral administration including intravenous administration. Also included are formulations including both the NK-1 receptor antagonist and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.
本文公开了一种神经激肽-1(NK-1)受体拮抗剂的新型药物制剂,适合肠外给药,包括静脉给药。还包括同时含有 NK-1 受体拮抗剂和地塞米松磷酸钠的制剂。这些药物制剂是稳定的水包油乳剂,用于非口服治疗呕吐,尤其适用于治疗正在接受高致呕吐癌症化疗的患者。